@CellisticCT announced today they will acquire @CelyadSA GMP grade cell therapy manufacturing capability, which includes facilities and all related personnel #ipsc#celltherapy — Read the release here: https://t.co/gv917mjx5X
Backed by a PE firm, Kiniciti has taken a majority stake in Belgium's Ncardia as its first step toward building a group of complementary cell therapy tools and services companies https://t.co/SAqF42nwSx
Kiniciti Team is honored to announce that we are now a strategic partner with @NcardiaStemCell one of the world's leading iPSC companies. Read our news announcement here: https://t.co/aS5JVv10cv
#CellTherapy#pharmanews#biopharma#ipsc
Press Release: Kiniciti raises additional capital from Biospring Partners to fund its global platform serving the Cell & Gene Therapy Industry https://t.co/e1zPEOomlc
#celltherapy#GeneTherapy#fundingthefuture @Biosprings
Kiniciti CEO @geoffreymglass and Chief Strategy Officer Jason Conner are attending the @alliancerm for Regenerative Medicine’s Cell & Gene Meeting on the Mesa! Organizers are expecting 3,000+ virtual and in-person partnering meetings to be scheduled during the conference,
On May 26, Kiniciti CEO @geoffreymglass will be participating in a virtual salon on “Investing at the Speed of Innovation”.
Join us as we discuss this exciting time of rapid innovation in developing cell and gene therapies, and how leading investors decide what technologies are
Kiniciti welcomes Ehsan Abbaszadeh as our new Executive Director, Corporate Development. Ehsan has over a decade of experience in the medical technology space and most recently was managing director at a private investment firm.
We are excited to have Ehsan join Team Kiniciti!
Kiniciti Welcomes Two Cell and Gene Therapy Industry Leaders to its Advisory Board: Dr. Denis Bedoret, chief executive officer at Imcyse, and Andrew Knudten, chief operating officer at Jaguar Gene Therapy. Welcome to the team! Read our full Press Release: https://t.co/hTAgyddpTL